Skip Navigation


NDT Advance Access originally published online on December 29, 2005
Nephrology Dialysis Transplantation 2006 21(3):579-581; doi:10.1093/ndt/gfi282
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/3/579    most recent
gfi282v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Navarra, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navarra, S. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Immune therapy of lupus: what is on the horizon?

Sandra V. Navarra

Section of Rheumatology, Clinical Immunology and Osteoporosis, University of Santo Tomas, Manila, Philippines

Correspondence and offprint requests to: Sandra V. Navarra, Section of Rheumatology, Clinical Immunology and Osteoporosis, University of Santo Tomas, Manila, The Philippines. Email: snavarra@pacific.net.ph

Keywords: lupus nephritis; immunotherapy; anti-cytokine; treatment; monoclonal antibodies

The first 10% of the full text of this article appears below.

Systemic lupus erythematosus (SLE) is a complex disease which has posed a continuing challenge to scientists and clinicians of diverse areas of specialization. It serves as a model for the study of the mechanisms of autoimmunity—providing an important basis for the development of novel targeted therapies in lupus and related conditions.

The pathophysiology of SLE stems from the abnormal clearance of apoptotic cells and/or endothelial activation. Material from dying cells such as apoptotic blebs that are not efficiently removed may act as antigenic stimuli and lead to the development of autoantibodies with consequent formation of immune complexes and an inflammatory response in a variety of organ systems [1]. This . . . [Full Text of this Article]



   Anti-cytokines
 


   Targeting B cells
 


   Inhibiting co-stimulation
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?